Antigen

Dr Pirkko Muhonen, Senior Field Application Scientist, Nucleic Acid Therapeutics, at Thermo Fisher Scientific, shares what’s next for RNA-based medicine post-pandemic with DDW. With SARS-CoV-2 circulating the globe and leading to over five million deaths worldwide1, all eyes are on the critical role messenger RNA (mRNA) vaccines are playing in helping to fight the ongoing […]

Swedish biotech company Salipro Biotech has entered into a collaboration and licensing agreement with AbCellera for access to its proprietary Salipro Platform, which stabilises challenging G protein coupled receptor (GPCR), ion channel and transporter antigens.  “We are excited to build on the success of our previous studies and deepen our relationship with the team at AbCellera,” said Jens Frauenfeld, CEO of Salipro Biotech. “We look forward […]

The Native Antigen Company has won ‘The Best Covid-19 Responder’ at the OBN 2020 Awards. The award recognises the Company’s contribution to the fight against Covid-19. The Native Antigen Company has utilised its expertise in developing high-quality reagents to play a major role in the global response to SARS-CoV-2. In February 2020, the company was […]

The pressure to take your drug to market faster is increasing. To achieve a successful journey to the first clinical trial phase in the fastest time possible, Eppendorf has identified three key elements that it is addressing in an eBook.  Comply with audit requirements and relevant certifications  Drive process efficiencies with increased speed whilst not […]